Implications for treating appropriate patients with a direct oral anticoagulant, such as rivaroxaban, based on more recent trial data and a new indication for the prevention of venous thromboembolism.
This analysis suggests serum IL-13 levels are lower in bullous pemphigoid patients than in healthy controls and pemphigus vulgaris patients.
At 2025 So Cal Psych, McGuire shared insights on diagnosing bipolar depression, treating agitation in dementia, and managing mental health challenges in patients who stutter.
Christopher Bunick, MD, PhD, and Lindsay Ackerman, MD, FAAD, discuss how Janus kinase (JAK) inhibitors are revolutionizing atopic dermatitis treatment by providing faster, deeper, and…
Auchus discusses his recent presentation on the CATALYST trial, investigating the characteristics of patients with difficult-to-treat T2D because of hypercortisolism.
Lifestyle intervention yielded greater maintained weight loss 12 months after discontinuing semaglutide than without.
Hosts Kimberly Brown and Nancy Reau discuss policy, clinical, and structural milestones enabling HCV elimination efforts and critical gaps impeding progress.
Shaker shares how allergist-immunologists can use brief CBT, motivational interviewing, and risk reframing to shift patients’ fear of their food allergies into confidence.
Capricor Therapeutics intends to resubmit a BLA for the potential first-in-class treatment with topline data from the ongoing HOPE-3 trial in Q3 2025.
An audio recap of the top 5 stories in healthcare news from the week of 06/30-07/06.
Hosts Kimberly Brown and Nancy Reau discuss policy, clinical, and structural milestones enabling HCV elimination efforts and critical gaps impeding progress.
